argenx
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 2008-01-01
- Employees
- -
- Market Cap
- $31.2B
- Website
- https://www.argenx.com/
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults with Multifocal Motor Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- argenx
- Target Recruit Count
- 100
- Registration Number
- NCT06742190
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- argenx
- Target Recruit Count
- 580
- Registration Number
- NCT06684847
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults with Systemic Sclerosis
- Conditions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- argenx
- Target Recruit Count
- 81
- Registration Number
- NCT06655155
- Locations
- 🇺🇸
Arizona Arthritis and Rheumatology Associates, Phoenix, Arizona, United States
A Study to Assess Adults with CIDP Transitioning from IVIg to Efgartigimod PH20 SC
- Conditions
- Interventions
- First Posted Date
- 2024-10-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- argenx
- Target Recruit Count
- 25
- Registration Number
- NCT06637072
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults with Ocular Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- argenx
- Target Recruit Count
- 124
- Registration Number
- NCT06558279
- Locations
- 🇺🇸
SFM Clinical Research, LLC, Boca Raton, Florida, United States
🇺🇸National Neuromuscular Research Institute, Austin, Texas, United States
🇺🇸Neurology Offices of South Florida, Boca Raton, Florida, United States
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- argenx
- Target Recruit Count
- 63
- Registration Number
- NCT06544499
- Locations
- 🇺🇸
Clinical Research Alliance Inc., Westbury, New York, United States
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- argenx
- Target Recruit Count
- 30
- Registration Number
- NCT06503731
- Locations
- 🇨🇦
London Health Sciences Centre, London, Canada
🇺🇸The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center, Richmond, Virginia, United States
A Safety and Efficacy Study of ARGX-119 in Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- argenx
- Target Recruit Count
- 60
- Registration Number
- NCT06441682
- Locations
- 🇩🇰
Bispebjerg University Hospital, Kopenhagen, Denmark
🇸🇪Akademiskt specialistcentrum Karolinska Institutet, Stockholm, Sweden
🇧🇪UZ Leuven, Leuven, Belgium
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
- Conditions
- Interventions
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- argenx
- Target Recruit Count
- 15
- Registration Number
- NCT06436742
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇺🇸Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇫🇷CHU - Hospital de la Timone, Marseille, France
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age with Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- argenx
- Target Recruit Count
- 12
- Registration Number
- NCT06392386
- Locations
- 🇫🇷
AP-HM- Hôpital de La Timone, Marseille, France
🇮🇹Istituto G Gaslini Ospedale Pediatrico IRCCS, Genova, Italy
🇺🇸Neurology Rare Disease Center, Denton, Texas, United States